REGENXBIO Inc
Uždarymo kaina
SektoriusSveikatos priežiūra
9.87 -0.5
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
9.77
Max
10.96
Pajamos | -23M -90M |
|---|---|
Pardavimai | -24M 6.4M |
Pelnas, tenkantis vienai akcijai | -1.72 |
Pelno marža | -1,408.588 |
Darbuotojai | 371 |
EBITDA | -14M -77M |
Rekomendacijos | Stiprus pirkimas |
|---|---|
12 mėnesių prognozė | +109.53% upside |
Kitas uždarbis | 2026-08-06 |
|---|
Rinkos kapitalizacija | -20M 500M |
|---|---|
Ankstesnė atidarymo kaina | 10.37 |
Ankstesnė uždarymo kaina | 9.87 |
Naujienos nuotaikos
By Acuity
38%
62%
114 / 342 reitingas Healthcare
REGENXBIO Inc Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Apie bendrovę REGENXBIO Inc
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland.